Eritropoyetina En La Anemia De La Prematuridad. Factores Neonatales Predictores De Transfusiones

Content Provider	Semantic Scholar
Author	Huerta, E. Sastre Álvarez, Beatriz Alonso Alonso, R. Montero Martín, Teresa Álvarez Izquierdo, F. Barbadillo Martín, I. Carpintero Rivas, Teresa Fernández, J. Suárez
Copyright Year	1998
Abstract	Objective: The objective of this study was to evaluate the efficiency of recombinant human erythropoietin (rHEPO) in the treatment of premature anemia and to analyze the relationship between the most common pathological processes (risk factors) in low birth weight premature babies with the need for transfusion. Patients and methods: A non-random case control study of 56 premature babies weighing 1500 gram and with a gestational age of 32 weeks, 28 treated with rHEPO and 28 without treatment, was carried out. The treated group received 200 IU/kg of rHEPO subcutaneously 3 days/week from the second week of life onwards for 4 weeks. An ferrous sulphate supplement was also administered orally in doses of 5 mg/kg/day, as was 25 mg/day of vitamin E and a multivitamin complex. Hemoglobin, hematocrit, reticulocytes, granulocyte and platelets were measured, as well as iron and ferritin levels at the beginning and end of the treatment. Two periods were established.: The first, before rHEPO treatment or the first two weeks of life, and the second, after treatment or the second week of life. Hematic transfusion needs were analyzed with respect to the administration of rHEPO and the severe neonatal pathologies established in both periods of time. Results: The group treated presented an increase in the number of reticulocytes at the end of treatment, as well as a decrease in the levels of sideropenia and ferritin. The values of Hg and Hct remained stable throughout treatment for children who received rHEPO. The transfusion indication was inversely related to weight and gestational age. For previous transfusions, the best predictors were: SDR (p = 0.04), mechanical ventilation period in days (p = 0.01) and sepsis (p = 0.04). With respect to late transfusions, risk factors were sepsis (p = 0.003) and bronchopulmonary dysplasia (p = 0.012). The number of transfusions per child were 0.75 ± 0.75 in the first period in both groups. In the second period the group treated with rHEPO received 0.5 ± 0.9 transfusions/child and the untreated received 1.5 ± 0.8 transfusions/child (p<0.001). Conclusions: Treatment with rHEPO was effective in reducing the number of transfusions, mainly in stable newborns with a weight greater than 1200 gram and a gestational age equal to or greater than 30 weeks. The risk of needing late transfusions was three times higher in the premature infants that did not receive treatment. Severe neonatal pathology is related to the necessity of transfusions, as well as the number of transfusions, in the period before administration and during treatment with rHEPO.
Starting Page	49
Ending Page	54
Page Count	6
File Format	PDF HTM / HTML
Volume Number	49
Alternate Webpage(s)	http://www.aeped.es/sites/default/files/anales/49-1-11.pdf
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article